Company Overview - Hologic, Inc. (HOLX) is a Massachusetts-based medical technology company with a market cap of $14.7 billion, specializing in women's health through diagnostic products, medical imaging systems, and surgical devices [1] Financial Performance - For fiscal Q4 2025, analysts project an adjusted EPS of $1.10, representing an 8.9% increase from $1.01 in the same quarter last year [2] - For fiscal 2025, the expected adjusted EPS is $4.24, up 3.9% year-over-year from $4.08 in fiscal 2024, with a further increase to $4.48 expected in fiscal 2026, reflecting a 5.7% year-over-year growth [3] Stock Performance - HOLX stock has declined 18% over the past 52 weeks, underperforming the S&P 500 Index, which gained 14.7%, and the Health Care Select Sector SPDR Fund, which declined by 6.7% during the same period [4] Recent Developments - On October 2, Hologic shares rose 1.3% following FDA clearance for its Panther Fusion® Gastrointestinal Bacterial and Expanded Bacterial Assays, which are designed to quickly detect common bacterial pathogens causing infectious gastroenteritis [5] Analyst Ratings - Analysts maintain a "Moderate Buy" rating for HOLX, with 20 analysts covering the stock: eight recommend "Strong Buy," two suggest "Moderate Buy," and ten advise "Hold." The mean price target of $75.25 indicates a potential upside of 12.3% from current price levels [6]